BUSINESS

• Opdivo Gets South Korea OK for 1st Line Esophageal Cancer
  March 24, 2023

• Detailed Data Out for PIII Zolbetuximab Study in 1st-Line Gastric Cancer: Astellas
  March 23, 2023

• Kowa Launches Global PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
  March 23, 2023

• Senju Starts Japan PIII for Dry Eye Med; Takeda to Be Distributor If Approved
  March 23, 2023

• Kobayashi Kako to Withdraw Marketing License on April 1
  March 23, 2023

• Pfizer Japan Starts Commercial Rollout of COVID-19 Pill Paxlovid
  March 23, 2023

• Opdivo-Yervoy Combo Approved for HCC in Taiwan
  March 23, 2023

• Eisai Publishes Updated Social Value Simulation for Lecanemab
  March 22, 2023

• Daiichi Sankyo Rolls Out Lung, Breast Cancer Data for HER3-Directed ADC
  March 22, 2023

• Mitsubishi Tanabe Files Canaglu OD Tablet Form in Japan
  March 22, 2023

• Xtandi Plus Leuprolide Meet PIII Goal in Non-Metastatic Prostate Cancer: Astellas
  March 20, 2023

• Takeda Updates Qdenga Peak Sales Estimate to US$1.6-2 Billion
  March 17, 2023

• Fujifilm to Make Foray into Drug Discovery CRO Business
  March 17, 2023

• Twymeeg No 1 in GP Promotion in January, Dayvigo Most Pitched for HP: Intage
  March 17, 2023

• CSL R&D Head Touts Cost-Effectiveness of Hemophilia Gene Therapy Hemgenix
  March 17, 2023

• Illumina Eyes Japan Launch of Comprehensive Genomic Profiling Test This Year
  March 16, 2023

• Paxlovid to Enter Normal Distribution from March 22: Pfizer Japan
  March 16, 2023

• Ono, PeptiDream in Deal for Macrocyclic Constrained Peptide Therapeutics
  March 16, 2023

• Iron Solution MonoVer Now Available in Japan; Donepezil Patch, Cresemba to Hit Market in April
  March 16, 2023

• Teijin Pharma Plans Pivot to Rare Diseases as Generics Eat into Feburic Sales
  March 15, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 143
• 144
• 145
• 146
• 147
• 148
• 149
• 150
• 151
• …
• Next ›
• 最終 »